Age-related macular degeneration and recent developments: New hope for old eyes?

Postgraduate Medical Journal

Volumn 83, Issue 979, 2007, Pages 301-307

  Morris, Brid ^a   Imrie, Fraser ^a   Armbrecht, Ana Maria ^a   Dhillon, Baljean ^a  

^a PRINCESS ALEXANDRA EYE PAVILION   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN;

ANGIOGENESIS; BLINDNESS; CATARACT EXTRACTION; CLINICAL FEATURE; CLINICAL TRIAL; DIETARY INTAKE; DISEASE ACTIVITY; DISEASE COURSE; DRUG HALF LIFE; DRUG SAFETY; EYE SURGERY; GENETIC ASSOCIATION; GEOGRAPHIC DISTRIBUTION; HUMAN; HYPERTENSION; INCIDENCE; LASER COAGULATION; META ANALYSIS; ONSET AGE; PATIENT REFERRAL; PREVALENCE; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING HABIT; SUNLIGHT; SYSTEMATIC REVIEW; TRANSPUPILLARY THERMOTHERAPY; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

HUMANS; MACULAR DEGENERATION;

EID: 34249101587     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2006.052944     Document Type: Review

References (49)

1. Evans J, Wormald R. Is the incidence of registrable age-related macular degeneration increasing? Br J Ophthalmol 1996;80(1):9-14.
2. Owen CG, Fletcher AE, Donoghue M, et al. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol 2003;87(3):312-7.
3. Weih LM, VanNewkirk MR, McCarty CA, et al. Age-specific causes of bilateral visual impairment. Arch Ophthalmol 2000;118(2):264-9.
4. Klein R, Klein BE, Moss SE. Relation of smoking to the incidence of age-related maculopathy. The Beaver Dam Eye Study. Am J Epidemiol 1998;147(2):103-10.
5. Christen WG, Glynn RJ, Manson JE, et al. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA 1996;276(14):1147-51.
6. Seddon JM, Willett WC, Speizer FE, et al. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 1996;276(14):1141-6.
7. Tomany SC, Wang JJ, Van Leeuwen R, et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 2004;111(7):1280-7.
8. Klein BE, Klein R, Lee KE, et al. Risk of incident age-related eye diseases in people with an affected sibling: the Beaver Dam Eye Study. Am J Epidemiol 2001;154(3):207-11.
9. Stone EM, Braun TA, Russell SR, et al. Missense variations in the fibulin 5 gene and age-related macular degeneration. N Engl J Med 2004;351(4):346-53.
10. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 2005;102(20):7227-32.
11. Klein R, Rowland ML, Harris MI. Racial/ethnic differences in age-related maculopathy. Third National Health and Nutrition Examination Survey. Ophthalmology 1995;102(3):371-81.
12. Klein R, Klein BE, Tomany SC, et al. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. Ophthalmology 2003;110(4):636-43.
13. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 1997;115(6):741-7.
14. Vinding T, Appleyard M, Nyboe J, et al. Risk factor analysis for atrophic and exudative age-related macular degeneration. An epidemiological study of 1000 aged individuals. Acta Ophthalmol (Copenh) 1992;70(1):66-72.
15. Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA 1994;272(18):1413-20.
16. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta-carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119(10):1417-36.
17. Seddon JM, Cote J, Rosner B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol 2003;121(12):1728-37.
18. Guymer RH, Chiu AW, Lim L, et al. HMG CoA reductase inhibitors (statins): do they have a role in age-related macular degeneration? Surv Ophthalmol 2005;50:194-206.
19. Tomany SC, Cruickshanks KJ, Klein R, et al. Sunlight and the 10-year incidence of age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol 2004;122(5):750-7.
20. Darzins P, Mitchell P, Heller RF. Sun exposure and age-related macular degeneration. An Australian case-control study. Ophthalmology 1997;104(5):770-6.
21. Klein R, Klein BE, Wong TY, et al. The association of cataract and cataract surgery, with the long-term incidence of age-related maculopathy. Arch Ophthalmol 2002;120:1551-8.
22. Wang JJ, Klein R, Smith W, et al. Cataract surgery and the 5 year incidence of late-stage age-related maculopathy: pooled findings from the Beaver Dam and Blue Mountains eye studies. Ophthalmology 2003;110:1960-7.
23. Richer S, Stiles W, Statkute L. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 2004;75(4):216-30.
24. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117(10):1329-45.
25. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Arch Ophthalmol 1986;104(5):694-701.
26. Matsuoka M, Ogata N, Otsuji T, et al. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol 2004;88(1):809-15.
27. D'Amico DJ, Goldberg MF, Hudson H, et al. Anecortave Acetate Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularisation in age-related macular degeneration: twelve-month clinical outcomes, Ophthalmology 2003;110:2372-83.
28. Slakter JS, Bochow TW, D'Amico DJ, et al. Anecortave Acetate Clinical Study Group. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularisation in age-related macular degeneration. Ophthalmology 2006;113:3-13.
29. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF Inhibition Study in Ocular Neovascularisation Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351(27):2805-16.
30. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med, 2006;355, 1419-31.
31. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med, 2006;355, 1432-44.
32. Michels S. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-47.
33. Rosenfeld PJ, Intravitreal Avastin: the low cost alternative to Lucentis? Am J Ophthalmol 2006;142:141-3.
34. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9.
35. Mori K, Gelbach P, Ando A, et al. Regression of ocular neovascularisation in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2002;43:2428- 34.
36. Rasmussen H, Chu KW, Campochiaro P, et al. Clinical protocol. An open-label, phase I, single administration, dose escalation of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001;12:2029-32.
37. Myint K, Armbrecht AM, Mon S, et al. Transpupillary thermotherapy for the treatment of occult CNV in age-related macular degeneration: a prospective randomized controlled pilot study. Acta Ophthalmol Scand 2006;84(3):328-32.
38. Stolba U, Krebs I, Lamar PD, et al. Long term results after transpupillary thermotherapy in eyes with occult choroidal neovascularisation associated with age related macular degeneration. Br J Ophthalmol 2006;90(2):158-61.
39. Maberley DA, Chew H, Ma P, et al. Comparison of photodynamic therapy and transpupillary thermotherapy for subfoveal choroidal neovascularization due to age-related macular degeneration. Can J Ophthalmol 2005;40(3):378-83.
40. Shiraga F, Ojima Y, Matsuo T, et al. Feeder vessel photocoagulation of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 1998;105(4):662-9.
41. Flower RW. Optimizing treatment of choroidal neovascularization feeder vessels with age-related macular degeneration. Am J Ophthalmol 2002;134(2):228-39.
42. Hawkins BS, Bressler NM, Miskala PH, et al. Surgery for subfoveal choroidal neovascularisation in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology 2004;111(11):1967-80.
43. Abdel-Meguid A, Lappas A, Hartmann K, et al. One year follow up of macular translocation with 360 degree retinotomy in patients with age related macular degeneration. Br J Ophthalmol 2003;87(5):615- 21.
44. Lai JC, Lapolice DJ, Stinnett SS, et al. Visual outcomes following macular translocation with 360-degree peripheral retinectomy. Arch Ophthalmol 2002;120(10):1317-24.
45. Mruthyunjaya P, Stinnett SS, Toth CA. Change in visual function after macular translocation with 360 degrees retinectomy for neovascular age-related macular degeneration. Ophthalmology 2004;111(9):1715- 24.
46. Toth CA, Freedman SA. Macular translocation with 360-degree peripheral retinectomy: impact of technique and surgical experience on visual outcomes. Retina 2001;21(4):293-303.
47. Armbrecht AM, Aspinall PA, Dhillon B. A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration. Br J Ophthalmol 2004;88(10):1270-3.
48. Rovner BW, Zisselman PM, Shmuely-Dulitzki Y. Depression and disability in older people with impaired vision: a follow-up study. J Am Geriatr Soc 1996;44(2):181-4.
49. Stuck AE, Walthert JM, Nikolaus J, et al. Risk factors for functional status decline in community-living elderly people: a systematic literature review. Soc Sci Med 1999;48(4):445-69.